Börsipäev 26.august
Kommentaari jätmiseks loo konto või logi sisse
-
SGP Bernstein upgrades to Mkt Perform from Underperform based on valuation, as the stock has fallen to their $15 target; firm continues to believe the mkt fails to fully reflect two fundamental issues: declining hepatitis revs and the timing of Zocor/Zetia profits; although firm thinks it's important to let the hep-C failure be reflected in the stock before buying, and even though they expect delayed Zocor/Zetia profits, they acknowledge that the stock may still appreciate in anticipation of an eventual payoff
